PureTech Health's (PRTC) Sell (D) Rating Reiterated at Weiss Ratings

Key Points

• PureTech Health's stock has received a "sell (d)" rating from Weiss Ratings, indicating analysts' concerns about the company's performance.
• The company has seen a significant fluctuation in stock price over the past year, with a low of $13.30 and a high of $24.99.
• Several hedge funds have increased their stakes in PureTech Health, including Pentwater Capital Management, which grew its position by 39.2% in the first quarter.

PureTech Health (NASDAQ:PRTC - Get Free Report)'s stock had its "sell (d)" rating reiterated by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

PureTech Health Price Performance

NASDAQ:PRTC opened at $18.77 on Wednesday. PureTech Health has a 1-year low of $13.30 and a 1-year high of $24.99. The firm has a fifty day simple moving average of $17.55 and a 200 day simple moving average of $17.67.

Hedge Funds Weigh In On PureTech Health

Several hedge funds and other institutional investors have recently made changes to their positions in PRTC. Pentwater Capital Management LP grew its stake in shares of PureTech Health by 39.2% in the first quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after buying an additional 9,449 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of PureTech Health in the second quarter valued at $29,000. Finally, Diadema Partners LP bought a new position in shares of PureTech Health in the second quarter valued at $126,000. 0.04% of the stock is owned by institutional investors.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.